Safety study of BIIB147 for adults with ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALS.
- You do not have certain genetic changes in the SOD1 or FUS genes.
- Your breathing strength is at least 50% of what is expected for your age, sex, and height.
- If you take riluzole, you must be on a stable dose for at least 30 days before the study starts.
- You are not currently on permanent ventilation (using a breathing machine more than 22 hours a day).
- You have not had a blood clot in your legs or lungs in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and whether it can slow the progression of the disease.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.